X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
apatinib (325) 325
chemotherapy (150) 150
index medicus (133) 133
oncology (131) 131
cancer (93) 93
vascular endothelial growth factor (92) 92
humans (87) 87
angiogenesis (85) 85
metastasis (79) 79
cancer therapies (77) 77
pyridines - therapeutic use (63) 63
tumors (63) 63
double-blind (62) 62
inhibitor (62) 62
neoplasms. tumors. oncology. including cancer and carcinogens (55) 55
drug therapy (53) 53
stomach cancer (51) 51
therapy (51) 51
care and treatment (49) 49
patients (49) 49
female (48) 48
bevacizumab (46) 46
lung cancer (46) 46
phase-ii (46) 46
targeted therapy (46) 46
adenocarcinoma (45) 45
endothelial growth-factor (45) 45
kinases (42) 42
male (42) 42
antineoplastic agents - therapeutic use (41) 41
medicine, general & internal (41) 41
treatment outcome (41) 41
gastric cancer (40) 40
middle aged (40) 40
biotechnology & applied microbiology (39) 39
abridged index medicus (38) 38
efficacy (38) 38
oncotargets and therapy (38) 38
pharmacology & pharmacy (36) 36
trial (36) 36
case report (34) 34
research (34) 34
vegf (34) 34
clinical case report (33) 33
development and progression (33) 33
analysis (32) 32
health aspects (32) 32
patient outcomes (32) 32
multicenter (31) 31
multicenter phase-ii (31) 31
pyridines - administration & dosage (31) 31
hypertension (30) 30
medical prognosis (29) 29
original research (29) 29
tyrosine kinase (29) 29
pyridines - adverse effects (28) 28
safety (28) 28
5700 (27) 27
breast cancer (27) 27
tyrosine (27) 27
yn968d1 (27) 27
adult (26) 26
drug dosages (26) 26
antineoplastic agents (25) 25
aged (24) 24
antimitotic agents (24) 24
pyridines - pharmacology (24) 24
gastric-cancer (23) 23
lung neoplasms - drug therapy (23) 23
open-label (23) 23
clinical trials (22) 22
expression (22) 22
hepatocellular carcinoma (22) 22
phase-iii trial (22) 22
protein kinase inhibitors - therapeutic use (22) 22
cell biology (21) 21
disease-free survival (21) 21
growth (21) 21
liver cancer (21) 21
mutation (21) 21
vegfr-2 (21) 21
animals (20) 20
apoptosis (20) 20
hospitals (20) 20
placebo (20) 20
radiation therapy (20) 20
radiotherapy (20) 20
survival (19) 19
antineoplastic agents - adverse effects (18) 18
breast-cancer (18) 18
combination (18) 18
medicine, research & experimental (18) 18
studies (18) 18
colorectal cancer (17) 17
sorafenib (17) 17
usage (17) 17
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (17) 17
antineoplastic agents - administration & dosage (16) 16
docetaxel (16) 16
gastroesophageal junction (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Academic radiology, ISSN 1076-6332, 07/2019
The goal of this study was to determine the clinical efficacy and safety of drug-eluting bead (DEB) transarterial chemoembolization (TACE) in combination with... 
Journal Article
Oncotarget, ISSN 1949-2553, 05/2018, Volume 9, Issue 36, p. 24548
Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs,... 
Journal Article
Oncotarget, ISSN 1949-2553, 09/2018, Volume 9, Issue 72, pp. 33734 - 33738
Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one... 
Apatinib | Angiogenesis | Targeted therapy | Sarcomatoid carcinoma
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 63, pp. 32262 - 32270
Apatinib is a novel small molecular drug targeting vascular endothelial growth factor receptor-2 (VEGFR-2), which is being studied in multiple tumor types. We... 
Apatinib | Hypertension | Hand-foot-syndrome | Meta-analysis | Proteinuria
Journal Article
Zhongguo fei ai za zhi = Chinese journal of lung cancer, ISSN 1009-3419, 11/2018, Volume 21, Issue 11, pp. 880 - 884
Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 11/2019, Volume 143, pp. 27 - 45
Although paclitaxel plus ramucirumab has been recommended as the preferred second-line strategy, other regimens also display potentially comparable efficacies.... 
Refractory | Apatinib | Second-line systemic therapy | Paclitaxel plus ramucirumab | Nivolumab
Journal Article
INTERNATIONAL JOURNAL OF CANCER, ISSN 0020-7136, 10/2014, Volume 135, Issue 8, pp. 1961 - 1969
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial... 
VEGFR2 | 1ST-LINE TREATMENT | apatinib | TYROSINE KINASE | OPEN-LABEL | TUMOR ANGIOGENESIS | SUNITINIB PLUS PACLITAXEL | RENAL-CELL CARCINOMA | TRIAL | ONCOLOGY | metastatic breast cancer | IN-VIVO | triple negative | DOUBLE-BLIND | EXPRESSION
Journal Article
Medicine (United States), ISSN 0025-7974, 11/2017, Volume 96, Issue 45
Journal Article
Medicine (United States), ISSN 0025-7974, 04/2018, Volume 97, Issue 15
Journal Article
Chinese Journal of Interventional Imaging and Therapy, ISSN 1672-8475, 07/2018, Volume 15, Issue 7, pp. 443 - 446
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 02/2019, Volume 509, Issue 2, pp. 529 - 534
To investigate the effect of local treatment of gadolinium-polyethylene glycol (Gd-PEG) hydrogel containing apatinib injected into hepatocellular carcinoma... 
Apatinib | VEGFR2 | Gadolinium | Hepatocellular carcinoma | Hydrogel | CD34 | BIOPHYSICS | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR ANGIOGENESIS | INHIBITOR | CANCER
Journal Article
Medicine (United States), ISSN 0025-7974, 11/2017, Volume 96, Issue 45
Journal Article
by Ji G and Hong L and Yang P
OncoTargets and Therapy, ISSN 1178-6930, 08/2016, Volume 2016, Issue Issue 1, pp. 4989 - 4992
Guanghui Ji,1 Liu Hong,2 Ping Yang3 1Department of Traditional Chinese Medicine, 2Department of Pathology, 3Department of Oncology, PLA Navy General Hospital,... 
targeted therapy | apatinib | angiogenesis inhibitor | Angiosarcoma | chemotherapy
Journal Article
Cell Cycle, ISSN 1538-4101, 05/2018, Volume 17, Issue 10, pp. 1235 - 1244
Apatinib is a novel tyrosine kinase inhibitor that targets VEGFR2 signal and exhibits potent anti-tumor effects in human cancers. In this study, we aim to... 
Apatinib | VEGFR2 signal | cell cycle | Cervical cancer | cellular proliferation | YN968D1 | STATISTICS | VEGF | CIN | EXPRESSION | CELL BIOLOGY
Journal Article
by Jeong JH and Nguyen HK and Lee JE and Suh W
International Journal of Nanomedicine, ISSN 1178-2013, 07/2016, Volume 2016, Issue default, pp. 3101 - 3109
Ji Hoon Jeong,1,* Hong Khanh Nguyen,2,* Jung Eun Lee,1 Wonhee Suh2 1School of Pharmacy, Sungkyunkwan University, Suwon, 2College of Pharmacy, Chung-Ang... 
Apatinib | vascular endothelial growth factor | permeability | nanoparticle | diabetes
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 6, pp. 7175 - 7181
This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line... 
Apatinib | Non-small-cell lung cancer | Angiogenesis | VEGFR-2
Journal Article
Chinese Journal of Clinical Oncology, ISSN 1000-8179, 2018, Volume 45, Issue 7, pp. 362 - 365
Journal Article
Chinese Journal of Lung Cancer, ISSN 1009-3419, 2017, Volume 20, Issue 11, pp. 761 - 768
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.